Down-Regulation of CEND1 Expression Contributes to The Progression and Temozolomide Resistance of Glioma

Objective: This study was conducted to clarify the expression characteristics of cell cycle exit and neuronal differentiation1 (CEND1) in glioma and its effects on the proliferation, migration, invasion, and resistance to temozolomide (TMZ) ofglioma cells.Materials and Methods: In this experimental...

Full description

Bibliographic Details
Published in:	Cell Journal
Main Authors:	Houjun Zhou, Bai Peng
Format:	Article
Language:	English
Published:	Royan Institute (ACECR), Tehran 2023-04-01
Subjects:	cend1 glioma proliferation temozolomide
Online Access:	https://www.celljournal.org/article_699793_4947675c2dfb8a990fa2b06e50c194ec.pdf

Similar Items

Difference in the Inhibitory Effect of Temozolomide on TJ905 Glioma Cells and Stem Cells
by: Feng Jin, et al.
Published: (2017-09-01)

Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights
by: Hengzeng Li, et al.
Published: (2025-06-01)

A Dot-Blot Screening for Identifying the Temozolomide-Regulated Proteins as Potential Targets for Glioma Multi-OMICS Studies
by: Anna Maria Bielecka-Wajdman, et al.
Published: (2024-10-01)

Progress of temozolomide in the treatment of recurrent high-grade gliomas
by: Jin-duo LI, et al.
Published: (2013-12-01)

Temozolomide Chronotherapy in Glioma: A Systematic Review
by: Jason L. Jia, et al.
Published: (2023-02-01)

Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis
by: Jun-Hai Tang, et al.
Published: (2019-12-01)

Two decades of progress in glioma methylation research: the rise of temozolomide resistance and immunotherapy insights
by: Xianhao Huo, et al.
Published: (2024-09-01)

Identification and verification of the temozolomide resistance feature gene DACH1 in gliomas
by: Qiang Gu, et al.
Published: (2023-03-01)

Knockdown ATG4C inhibits gliomas progression and promotes temozolomide chemosensitivity by suppressing autophagic flux
by: Zhi-peng Wen, et al.
Published: (2019-07-01)

Sertindole inhibits autophagic flux and glioma progression
by: Baiyang Liu, et al.
Published: (2023-06-01)

Folic acid‐decorated astrocytes‐derived exosomes enhanced the effect of temozolomide against glioma
by: Hong‐Ming Liu, et al.
Published: (2024-05-01)

Case report: Temozolomide induced hypermutation indicates an unfavorable response to immunotherapy in patient with gliomas
by: Jiapeng Liu, et al.
Published: (2024-04-01)

Long non-coding RNA in glioma: novel genetic players in temozolomide resistance
by: Jungwook Roh, et al.
Published: (2023-12-01)

Pharmacoeconomic evaluation of original and generic temozolomide capsules in the treatment of glioma
by: Ming Gu, et al.
Published: (2023-06-01)

Temozolomide with Radiation Therapy in High Grade Brain Gliomas: Pharmaceuticals Considerations and Efficacy;A Review Article
by: Demetrios Chaldeopoulos, et al.
Published: (2009-04-01)

Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma
by: Xiaoying Hou, et al.
Published: (2023-03-01)

Engrailed 2 (EN2) acts as a glioma suppressor by inhibiting tumor proliferation/invasion and enhancing sensitivity to temozolomide
by: Tengfei Li, et al.
Published: (2020-03-01)

The landscape of circRNAs in gliomas temozolomide resistance: Insights into molecular pathways
by: Alireza Mafi, et al.
Published: (2024-12-01)

Research progress of drug resistance mechanism of temozolomide in the treatment of glioblastoma
by: Hao Wu, et al.
Published: (2024-11-01)

The efficacy and adverse events of bevacizumab combined with temozolomide in the treatment of glioma: a systemic review and meta-analysis of randomized controlled trials
by: SiYao Wei, et al.
Published: (2024-07-01)

A MRI-based radiomics model for predicting the response to anlotinb combined with temozolomide in recurrent malignant glioma patients
by: Yurong Li, et al.
Published: (2023-08-01)

Glycogenolysis in Acquired Glioma Resistance to Temozolomide: A Role for the [Ca2+]i-dependent Activation of Na,K-ATPase/ERK1/2 Signaling
by: Junnan Xu, et al.
Published: (2018-08-01)

Novel diagnostic and therapeutic approaches to malignant glioma
by: Swiss Medical Weekly
Published: (2011-05-01)

Hypoxic microenvironment-induced exosomes confer temozolomide resistance in glioma through transfer of pyruvate kinase M2
by: Guofu Li, et al.
Published: (2024-04-01)

MiR‐634 sensitizes glioma cells to temozolomide by targeting CYR61 through Raf‐ERK signaling pathway
by: Zhigang Tan, et al.
Published: (2018-03-01)

CUL4B Promotes Temozolomide Resistance in Gliomas by Epigenetically Repressing CDNK1A Transcription
by: Xiang Ye, et al.
Published: (2021-04-01)

Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma
by: Chenyu Ding, et al.
Published: (2021-05-01)

BRD4 Degradation Enhanced Glioma Sensitivity to Temozolomide by Regulating Notch1 via Glu‐Modified GSH‐Responsive Nanoparticles
by: Linbin Yi, et al.
Published: (2024-12-01)

Mutations in the <i>PIK3C2B</i>, <i>ERBB3</i>, <i>KIT</i>, and <i>MLH1</i> Genes and Their Relationship with Resistance to Temozolomide in Patients with High-Grade Gliomas
by: León Darío Ortiz Gómez, et al.
Published: (2024-12-01)

The efficacy of targeted therapy combined with radiotherapy and temozolomide-based chemotherapy in the treatment of glioma: A systemic review and meta-analysis of phase II/III randomized controlled trials
by: Yifan Ma, et al.
Published: (2023-01-01)

Transcriptomic analysis identifies the neuropeptide cortistatin (CORT) as an inhibitor of temozolomide (TMZ) resistance by suppressing the NF-κB-MGMT signaling axis in human glioma
by: Zongze He, et al.
Published: (2024-05-01)

99mTc-Tetrofosmin uptake correlates with the sensitivity of glioblastoma cell lines to temozolomide
by: George Alexiou, et al.
Published: (2017-01-01)

Study on mechanism of thalidomide combined with temozolomide to suppress proliferation of U251 glioma cell in vitro
by: Song GAO, et al.
Published: (2010-10-01)

The role of KDM4A‐mediated histone methylation on temozolomide resistance in glioma cells through the HUWE1/ROCK2 axis
by: Xi‐Xi Li, et al.
Published: (2024-02-01)

Expression and Prognostic Role of Glia Maturation Factor-γ in Gliomas
by: Junhui Liu, et al.
Published: (2022-06-01)

Drug metabolism-related gene ABCA1 augments temozolomide chemoresistance and immune infiltration abundance of M2 macrophages in glioma
by: Yuanliang Yan, et al.
Published: (2023-09-01)

IL-18, a therapeutic target for immunotherapy boosting, promotes temozolomide chemoresistance via the PI3K/AKT pathway in glioma
by: Huangyi Ji, et al.
Published: (2024-10-01)

Plumbagin Enhanced Inhibitory Effect of Temozolomide on Migration and Invasion of Human Glioma U251 Cells Through E-cadherin
by: CAI Wei, et al.
Published: (2021-06-01)

Temozolomide and oral etoposide in children with recurrent malignant brain tumors
by: Antonio Ruggiero, et al.
Published: (2020-06-01)

Cranial Spinal Spreading of Canine Brain Gliomas after Hypofractionated Volumetric-Modulated Arc Radiotherapy and Concomitant Temozolomide Chemotherapy: A Four-Case Report
by: Gaetano Urso, et al.
Published: (2022-09-01)